



**Bolt Biotherapeutics To Present Preclinical Proof of Concept Data at  
American Association for Cancer Research (AACR) Conference**

**-- Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Platform Demonstrates  
Anti-Tumor Immunity in Preclinical Tumor Models --**

REDWOOD CITY, CA, February 27, 2019 – Bolt Biotherapeutics, Inc., a biotechnology company focused on unleashing the power of the immune system to achieve anti-tumor immunity in patients with its promising Immune-Stimulating Antibody Conjugate (ISAC) platform, today announced the forthcoming presentation of preclinical data on its Boltbody™ technology at the American Association for Cancer Research (AACR) Conference. The conference will be held March 29<sup>th</sup> through April 3<sup>rd</sup> in Atlanta, Georgia.

**Details relating to the presentation are as follows:**

**Abstract Title:** TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and antitumor immunity in pre-clinical models.

**Abstract Number:** 1559

**Date and Time:** Monday, April 1, 2019, 8am – 12pm EDT

**Session Category:** Immunology

**Session Title:** Therapeutic Antibodies 2

**Location:** Georgia World Congress Center, Exhibit Hall B, Poster Section 25, Poster Board 28

“We are pleased that the first public presentation of our Boltbody™ technology will occur at the AACR Annual Meeting,” stated David Dornan, Ph.D., senior vice president of research at Bolt Biotherapeutics. “Boltbody™ ISACs are a new class of therapeutics that harness the ability of toll-like receptor (TLR) agonists to convert cold tumors into immunologically hot tumors following systemic administration. We are rapidly advancing our lead Boltbody™ therapeutic toward the clinic based upon the promising data.”

“It is exciting to share the encouraging data generated by this unique technology which builds upon our growing understanding of the role of myeloid cells in generating effective anti-tumor immunity. Our poster will cover *in vitro* and *in vivo* data demonstrating that Boltbody™ ISACs have the capacity to eliminate tumors in preclinical models,” stated Ed Engleman, M.D., Bolt founder and co-director of the Immunology and Immunotherapy Research Program at the Stanford Cancer Institute.

**About Bolt Biotherapeutics’ Immune-Stimulating Antibody Conjugate (ISAC) Platform Technology**

The Boltbody™ platform consists of Immune-Stimulating Antibody Conjugates (ISAC) that harness the ability of TLR agonists to convert cold tumors into immunologically hot tumors (illuminating tumors to the immune system allowing them to be invaded by tumor killing cells). Boltbody™ ISACs have demonstrated the ability to

eliminate tumors following systemic administration in preclinical models and have also led to the development of immunologic memory.

**About Bolt Biotherapeutics**

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a private biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit [www.boltbio.com](http://www.boltbio.com).

**Contact:**

Jennifer Williams

Cook Williams Communications, Inc.

360-668-3701

[jennifer@cwcomm.org](mailto:jennifer@cwcomm.org)